Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 26;14(9):3009.
doi: 10.3390/jcm14093009.

A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood

Rodrigo Vázquez Frias  1 , André Hoerning  2 , Christian Boggio Marzet  3 , Martin C Michel  4
Affiliations
Review

A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood

Rodrigo Vázquez Frias et al. J Clin Med. .

Abstract

Background/Objectives: Hyoscine butylbromide (HBB) is a spasmolytic drug classified as indispensable by the World Health Organization. While mostly used in adults, it is also approved for use in adolescents and children aged 6 years and older. We have comprehensively reviewed the efficacy and safety of HBB in approved and off-label childhood indications. Results: Childhood studies covered an age range starting as early as 2 days. A randomized controlled trial (RCT) found a similar efficacy compared to paracetamol in the approved indication of abdominal cramps and pain. Among off-label uses, several studies demonstrate efficacy in general anesthesia and various diagnostic procedures, but the largest body of evidence relates to use in childbirth/labor, including 17 RCTs. While these largely focused on efficacy outcomes on the mother, fetal safety outcomes were reported in 12 of these studies, mostly as effects on the APGAR score and/or heart rate. The overall evidence supports safety in infants and children including those younger than the approved use age of 6 years and older. Conclusions: While only limited pediatric efficacy data from RCTs are available in the approved indications, data from thousands of patients in RCTs, case series, and non-randomized trials do not raise concerns on the safety and tolerability of HBB in childhood. Additional dedicated childhood studies, particularly RCTs, on efficacy are recommended.

Keywords: abdominal cramps; abdominal pain; childbirth; children; hyoscine butylbromide; infants; vomiting.

PubMed Disclaimer

Conflict of interest statement

R.V.F. has received support to attend courses, grants for research, act as a speaker or as part of advisory boards from AstraZeneca, Bayer, BioGaia, Biopas, Carnot, Chinoin, Columbia, Ferrer, Ipsen, Mayoly-Spindler, Medix, Megalabs, Nestlé, Nestlé Nutrititon Institute, Nutricia/Stendhal, Opella (a Sanofi company), Reckitt Benckiser/Mead Johnson, Sanofi, Schwabe Pharma, and Takeda. A.H. has received support to attend courses, grants for research, act as a speaker or part of advisory board for Abbvie, Danone, Ipsen, Janssen, Mirum, Orphalan, Pfizer, Sanofi, and Takeda. C.B.M. has received support to attend courses, grants for research, act as a speaker or as part of advisory boards from Abbott, Bayer, Biocodex, Biogaia, B-Life, Carnot, Cassará, Danone, Nestlé, Nutricia, Opella (a Sanofi company), Reckitt Benckiser/Mead Johnson Sanofi, and Siegfried. M.C.M. is a paid consultant to Opella, a Sanofi company, on several projects including the project reflected in this manuscript. MCM has not, however, received a honorarium for authorship of this paper. Opella (a Sanofi company) had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Comparison of effects of HBB and paracetamol on non-specific colicky abdominal pain in a head-to-head RCT. Data are shown as means ± SD of the pain score (primary study endpoint) measured on a visual analog scale ranging from 0 to 100. Adapted from [17].
Figure 2
Figure 2
Approved (upper row) and off-label but intensively studied (lower row) indications where HBB inhibits (upper row) or promotes (lower row) an effect. For details see main text. Images used are from Servier Medical Art (SMART) (upper row) and courses.lumenlearning.com (lower row) under CC-BY 4.0.
See this image and copyright information in PMC

References

    1. Tytgat G.N. Hyoscine butylbromide: A review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67:1343–1357. doi: 10.2165/00003495-200767090-00007. - DOI - PubMed
    1. Müderrisoglu A.E., Becher K.F., Madersbacher S., Michel M.C. Cognitive and mood side effects of lower urinary tract medication. Expert Opin. Drug Saf. 2019;18:915–923. doi: 10.1080/14740338.2019.1652269. - DOI - PubMed
    1. Weiser T. Guideline recommendations for the treatment of abdominal pain (in irritable bowel syndrome) Evid. Self-Med. 2021;1:210010. doi: 10.52778/efsm.21.0264. - DOI
    1. Barbara G., Cremon C., Bellini M., Corsetti M., Di Nardo G., Falangone F., Fuccio L., Galeazzi F., Iovino P., Sarnelli G., et al. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP) Dig. Liver Dis. 2023;55:187–207. doi: 10.1016/j.dld.2022.11.015. - DOI - PubMed
    1. Schäfer E., Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon. Fortschr. Med. 1990;108:488–492. - PubMed

LinkOut - more resources